Organon partners with Huya to identify and develop Chinese biopharmaceuticals
Collaboration looks for opportunities to expand the Organon biotech research programs and facilitate links with China's biotech industry
Organon announced that it has signed a collaboration agreement with HUYA Bioscience International, LLC, (HUYA) to search for new, proprietary biopharmaceuticals or pharmaceutical compounds. As part of this collaboration, Organon has acquired an equity interest in HUYA.
HUYA, with offices in San Diego and Shanghai, identifies, licenses and develops Chinese drug candidates for commercialization in Western markets. Under the collaboration agreement, HUYA will support Organon in the sourcing and development of pharmaceutical or biopharmaceutical compounds in three specific therapeutic areas.
No financial details of the transaction were disclosed.
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Ben-Gurion University Signs R&D Agreement with German Company curasan AG
Roche Diagnostics Licenses the Technology used for the LightCycler System to BIOTECON
ImmunoGen, Inc. Announces Genentech's Renewal of Technology Access Agreement
Metabolium names chief operating officer and chief scientific director
XOMA Appoints Steven B. Engle President, Chief Executive Officer and Director
Apitope Receives Orphan Designation in the European Union for ATX-F8-117 for the treatment of Haemophilia A
Amsterdam Molecular Therapeutics’ Glybera Significantly Reduces the Risk of Pancreatitis in LPLD Patients
Archimedes Pharma Enrols First Patient in Phase III Programme for Nasalfent in Cancer Pain
The virulence of the Toxoplasma parasite identified
